Back to previous page

Indication and Important Safety Information

Video transcript

On Screen Text

INDICATION AND IMPORTANT SAFETY INFORMATION

AREXVY (RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

PLEASE SEE FULL PRESCRIBING INFORMATION AVAILABLE ON THIS WEBSITE.

On Screen Text

Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

Important Safety Information

  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
  • The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
  • Vaccination with AREXVY may not result in protection of all vaccine recipients

AREXVY (RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

PLEASE SEE FULL PRESCRIBING INFORMATION AVAILABLE ON THIS WEBSITE.

Audio

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older.

AREXVY is contraindicated in anyone with a history of severe allergic reaction to any component of AREXVY. And we know that appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY. Syncope may occur with association of administration of injectable vaccines including AREXVY. Procedures should be in place to avoid injury from fainting.

Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished response to AREXVY. The most commonly reported adverse reactions were injection site pain in about 60% of people; fatigue; myalgia; headache; and arthralgia. Vaccination with AREXVY may not result in protection of all vaccine recipients.

So, again, I think it's important for individuals to understand the safety information because of the things that we just discussed.

You want to pay attention and be able to have access to your patients that may have had an unwanted clinical response. So, make sure when your patient's getting vaccinated that your patient has the appropriate information in case something was to happen, because there are some adverse events.

On Screen Text

Intended for US healthcare professionals only.

Trademarks are owned by or licensed to the GSK group of companies.

©2023 GSK or licensor.

RSAVID230046 July 2023

Produced in USA.

Please see full Prescribing Information available on this website.

close